Endocrine Abstracts

Background: Small-bowel neuroendocrine tumours (SB-NET) commonly metastasise despite most being low grade. The NET nomogram developed, estimates 5- and 10-year survival in SB-NET by allocating scores for 15 clinicopathological parameters. We comparatively evaluated the prognostic power of this nomogram, the WHO/ENETS grading and AJCC/UICC staging systems.Methods: Patients with histologically-confirmed SB-NET were identified from databases at two tertiary...

Background: Neuroendocrine tumours of the appendix (ANET) are relatively indolent tumours typically identified incidentally at surgery for suspected appendicitis. The role of right hemicolectomy (RH) for tumours with ‘high risk’ features is debated. We compared the management of ANET at three centres against ENETS criteria for therapy selection.Methods: Retrospective review of all patients diagnosed with ANET at three tertiary centres. Patients...

Introduction: Novel molecular analytes are needed in small bowel neuroendocrine tumours (SBNETs) to better determine disease aggressiveness and predict treatment response.Aim of the study: To profile the global miRNome of SBNETs, and identify microRNAs (miRNAs) involved in tumour progression for use as potential biomarkers.Material and methods: Two independent miRNA profiling experiments were performed (n=90), including pr...

Background: Surgery is the only curative treatment for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), but the prediction of residual disease/recurrence is limited in the absence of optimal biomarkers. We examined whether a blood-based multianalyte neuroendocrine gene transcript assay (NETest) would define tumor cytoreduction and therapeutic efficacy.Methods: The NETest is a polymerase chain reaction–based analysis of 51 genes. Disease acti...